Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) is now available.
GenFleet Therapeutics announced that its shares will be included in the eligible stock lists of both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs starting March 9, 2026. This move will allow qualified mainland Chinese investors to directly trade the company’s Hong Kong-listed shares via the Shanghai and Shenzhen stock exchanges, potentially broadening its investor base and liquidity.
The company’s stock will also join several Hang Seng Index Series benchmarks from March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index. Index inclusion typically enhances visibility and may attract additional institutional and passive investment, reinforcing GenFleet’s positioning within the innovative drug sector and Hong Kong’s capital markets.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company focused on innovative drug development, with its shares listed in Hong Kong under stock code 2595. The company operates in the life sciences sector and targets investors in both mainland China and Hong Kong through its capital markets presence.
Average Trading Volume: 804,903
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$9.3B
Learn more about 2595 stock on TipRanks’ Stock Analysis page.